-
2
-
-
84892805731
-
Cancer statistics, 2014
-
24399786
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014. 64:9-29. doi: 10. 3322/caac.21208 PMID: 24399786
-
(2014)
CA Cancer J Clin.
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
4
-
-
66549092182
-
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
-
Casali PG, Jost L, Sleijfer S, Verweij J, Blay J-Y, Group Obot EGW. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009. 20: iv132-iv136.
-
(2009)
Ann Oncol.
, vol.20
, pp. iv132-iv136
-
-
Casali, P.G.1
Jost, L.2
Sleijfer, S.3
Verweij, J.4
Blay, J.-Y.5
-
5
-
-
84884206527
-
Treatment outcome of postoperative radiotherapy for retroperitoneal sarcoma
-
22984679
-
Lee HJ, Song SY, Kwon T-W, Yook JH, Kim S-C, Han D-J, et al. Treatment outcome of postoperative radiotherapy for retroperitoneal sarcoma. Radiat Oncol J. 2011. 29:260-268. doi: 10.3857/roj.2011. 29.4.260 PMID: 22984679
-
(2011)
Radiat Oncol J.
, vol.29
, pp. 260-268
-
-
Lee, H.J.1
Song, S.Y.2
Kwon, T.-W.3
Yook, J.H.4
Kim, S.-C.5
Han, D.-J.6
-
6
-
-
84867547132
-
Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma
-
22984684
-
Lee J, Park YJ, Yang DS, Yoon WS, Lee JA, Rim CH, et al. Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma. Radiat Oncol J. 2012. 30:62-69. doi: 10.3857/roj.2012.30.2.62 PMID: 22984684
-
(2012)
Radiat Oncol J.
, vol.30
, pp. 62-69
-
-
Lee, J.1
Park, Y.J.2
Yang, D.S.3
Yoon, W.S.4
Lee, J.A.5
Rim, C.H.6
-
7
-
-
0022387730
-
The human met oncogene is related to the tyrosine kinase oncogenes
-
4069211
-
Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, Rowley JD, et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature. 1985. 318:385-388. PMID: 4069211
-
(1985)
Nature.
, vol.318
, pp. 385-388
-
-
Dean, M.1
Park, M.2
Le Beau, M.M.3
Robins, T.S.4
Diaz, M.O.5
Rowley, J.D.6
-
8
-
-
0023661693
-
Scatterfactor is a fibroblast-derived modulator of epithelial cell mobility
-
2952888
-
Stoker M, Gherardi E, Perryman Mand Gray J. Scatterfactor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987. 327:239-242. PMID: 2952888
-
(1987)
Nature.
, vol.327
, pp. 239-242
-
-
Stoker, M.1
Gherardi, E.2
Perryman Mand Gray, J.3
-
9
-
-
0025771101
-
Scatter factor and hepatocyte growth factor are indistinguishable ligandsforthe MET receptor
-
1655405
-
Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligandsforthe MET receptor. EMBO J. 1991. 10:2867-2878. PMID: 1655405
-
(1991)
EMBO J.
, vol.10
, pp. 2867-2878
-
-
Naldini, L.1
Weidner, K.M.2
Vigna, E.3
Gaudino, G.4
Bardelli, A.5
Ponzetto, C.6
-
10
-
-
0025136830
-
Quantitation of cytokine-stimulated migration of endothelium and epithelium by a new assay using microcarrier beads
-
2137088
-
Rosen EM, Meromsky L, Setter E, Vinter DW, Goldberg ID. Quantitation of cytokine-stimulated migration of endothelium and epithelium by a new assay using microcarrier beads. Exp Cell Res. 1990. 186:22-31. PMID: 2137088
-
(1990)
Exp Cell Res.
, vol.186
, pp. 22-31
-
-
Rosen, E.M.1
Meromsky, L.2
Setter, E.3
Vinter, D.W.4
Goldberg, I.D.5
-
11
-
-
0024522988
-
Smooth muscle releases an epithelial cell scatter factor which binds to heparin
-
2537811
-
Rosen EM, Goldberg ID, Kacinski BM, Buckholz T, Vinter DW. Smooth muscle releases an epithelial cell scatter factor which binds to heparin. In Vitro Cell DevBiol. 1989. 25:163-173. PMID: 2537811
-
(1989)
Vitro Cell DevBiol.
, vol.25
, pp. 163-173
-
-
Rosen, E.M.1
Goldberg, I.D.2
Kacinski, B.M.3
Buckholz, T.4
Vinter, D.W.5
-
12
-
-
84555202728
-
MET signaling pathway: A rational target for cancer therapy
-
22042966
-
Appleman LJ. MET Signaling Pathway: A Rational Target for Cancer Therapy. J Clin Oncol. 2011. 29:4837-4838. doi: 10.1200/JCO.2011.37.7929 PMID: 22042966
-
(2011)
J Clin Oncol.
, vol.29
, pp. 4837-4838
-
-
Appleman, L.J.1
-
13
-
-
0028270761
-
Scatterfactor modulates the metastatic phenotype of the EMT6 mouse mammary tumor
-
8194880
-
Rosen EM, Knesel J, Goldberg ID, Jin L, Bhargava M, Joseph A, et al. Scatterfactor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. IntJCancer. 1994. 57:706-714. PMID: 8194880
-
(1994)
IntJCancer.
, vol.57
, pp. 706-714
-
-
Rosen, E.M.1
Knesel, J.2
Goldberg, I.D.3
Jin, L.4
Bhargava, M.5
Joseph, A.6
-
14
-
-
0036006814
-
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
-
11750879
-
Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002. 13:41-59. PMID: 11750879
-
(2002)
Cytokine Growth Factor Rev.
, vol.13
, pp. 41-59
-
-
Maulik, G.1
Shrikhande, A.2
Kijima, T.3
Ma, P.C.4
Morrison, P.T.5
Salgia, R.6
-
15
-
-
0034641890
-
A novel germ line juxtamembrane Met mutation in human gastric cancer
-
11042681
-
Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000. 19:4947-4953. PMID: 11042681
-
(2000)
Oncogene.
, vol.19
, pp. 4947-4953
-
-
Lee, J.H.1
Han, S.U.2
Cho, H.3
Jennings, B.4
Gerrard, B.5
Dean, M.6
-
16
-
-
80053559947
-
Activating mutation in MET oncogene in familial colorectal cancer
-
21970370
-
Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer. 2011. 11:424. doi: 10.1186/1471-2407-11-424 PMID: 21970370
-
(2011)
BMC Cancer.
, vol.11
, pp. 424
-
-
Neklason, D.W.1
Done, M.W.2
Sargent, N.R.3
Schwartz, A.G.4
Anton-Culver, H.5
Griffin, C.A.6
-
17
-
-
33947207989
-
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival
-
17332337
-
Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007. 67:2081-2088. PMID: 17332337
-
(2007)
Cancer Res.
, vol.67
, pp. 2081-2088
-
-
Lutterbach, B.1
Zeng, Q.2
Davis, L.J.3
Hatch, H.4
Hang, G.5
Kohl, N.E.6
-
18
-
-
79961028656
-
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: Their roles in tumor progression and prognostication of the patient
-
21478826
-
Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol. 2011. 24:1146-1155. doi: 10.1038/modpathol.2011.70 PMID: 21478826
-
(2011)
Mod Pathol.
, vol.24
, pp. 1146-1155
-
-
Yamamoto, S.1
Tsuda, H.2
Miyai, K.3
Takano, M.4
Tamai, S.5
Matsubara, O.6
-
19
-
-
79959731074
-
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
-
21673683
-
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011. 105:131-138. doi: 10.1038/bjc.2011.199 PMID: 21673683
-
(2011)
Br J Cancer.
, vol.105
, pp. 131-138
-
-
Miyamoto, M.1
Ojima, H.2
Iwasaki, M.3
Shimizu, H.4
Kokubu, A.5
Hiraoka, N.6
-
20
-
-
0029830062
-
Scatter factor expression and regulation in human glial tumors
-
8760595
-
Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D, et al. Scatter factor expression and regulation in human glial tumors. Int J Cancer. 1996. 67:248-255. PMID: 8760595
-
(1996)
Int J Cancer.
, vol.67
, pp. 248-255
-
-
Rosen, E.M.1
Laterra, J.2
Joseph, A.3
Jin, L.4
Fuchs, A.5
Way, D.6
-
21
-
-
0027445603
-
Met expression and sarcoma tumorigenicity
-
7693339
-
Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res. 1993. 53:5355-5360. PMID: 7693339
-
(1993)
Cancer Res.
, vol.53
, pp. 5355-5360
-
-
Rong, S.1
Jeffers, M.2
Resau, J.H.3
Tsarfaty, I.4
Oskarsson, M.5
Vande Woude, G.F.6
-
22
-
-
76549109409
-
Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma
-
20068147
-
Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010. 70:639-645. doi: 10.1158/0008-5472. CAN-09-1121 PMID: 20068147
-
(2010)
Cancer Res.
, vol.70
, pp. 639-645
-
-
Davis, I.J.1
McFadden, A.W.2
Zhang, Y.3
Coxon, A.4
Burgess, T.L.5
Wagner, A.J.6
-
23
-
-
33847066415
-
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition
-
17283122
-
Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, et al. TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition. Cancer Res. 2007. 67:919-929. PMID: 17283122
-
(2007)
Cancer Res.
, vol.67
, pp. 919-929
-
-
Tsuda, M.1
Davis, I.J.2
Argani, P.3
Shukla, N.4
McGill, G.G.5
Nagai, M.6
-
24
-
-
0030885470
-
Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors
-
9308731
-
Rao UN, Sonmez-Alpan E, Michalopoulos GK. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol. 1997. 28:1066-1070. PMID: 9308731
-
(1997)
Hum Pathol.
, vol.28
, pp. 1066-1070
-
-
Rao, U.N.1
Sonmez-Alpan, E.2
Michalopoulos, G.K.3
-
25
-
-
77954747187
-
Functional mapping of receptor tyrosine kinases in myxoid liposarcoma
-
20522586
-
Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, et al. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin Cancer Res. 2010. 16:3581-3593. doi: 10.1158/1078-0432. CCR-09-2912 PMID: 20522586
-
(2010)
Clin Cancer Res.
, vol.16
, pp. 3581-3593
-
-
Negri, T.1
Virdis, E.2
Brich, S.3
Bozzi, F.4
Tamborini, E.5
Tarantino, E.6
-
26
-
-
0030070087
-
Over-expression of hepatocyte growth factor in human Kaposi's sarcoma
-
8567112
-
Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, et al. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer. 1996. 65:168-172. PMID: 8567112
-
(1996)
Int J Cancer.
, vol.65
, pp. 168-172
-
-
Maier, J.A.1
Mariotti, M.2
Albini, A.3
Comi, P.4
Prat, M.5
Comogilio, P.M.6
-
27
-
-
31144451464
-
Expression of osteopontin and HGF/met in adult softtissue tumors
-
16258259
-
Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, et al. Expression of osteopontin and HGF/met in adult softtissue tumors. Cancer Biol Ther. 2005. 4:1336-1341. PMID: 16258259
-
(2005)
Cancer Biol Ther.
, vol.4
, pp. 1336-1341
-
-
Bramwell, V.H.1
Tuck, A.B.2
Wilson, S.M.3
Stitt, L.W.4
Cherian, A.K.5
Rorke, S.C.6
-
28
-
-
65249122512
-
Novel therapeutic inhibitors of the c-met signaling pathway in cancer
-
19318488
-
Eder JP, Vande Woude GF, Boerner SA, Lo Russo PM. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clin Cancer Res. 2009. 15:2207-2214. doi: 10.1158/1078-0432. CCR-08-1306 PMID: 19318488
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 2207-2214
-
-
Eder, J.P.1
Vande Woude, G.F.2
Boerner, S.A.3
Lo Russo, P.M.4
-
30
-
-
79955897803
-
Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
-
21575221
-
Hou J, Dong J, Sun L, Geng L, Wang J, Zheng J, et al. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. Journal of Translational Medicine. 2011. 9:64. doi: 10.1186/1479-5876-9-64 PMID: 21575221
-
(2011)
Journal of Translational Medicine.
, vol.9
, pp. 64
-
-
Hou, J.1
Dong, J.2
Sun, L.3
Geng, L.4
Wang, J.5
Zheng, J.6
-
31
-
-
84055212018
-
A Phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors
-
21976535
-
Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, et al. A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors. Clin Cancer Res. 2011. 17:7754-7764. doi: 10.1158/1078-0432. CCR-11-1002 PMID: 21976535
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 7754-7764
-
-
Rosen, L.S.1
Senzer, N.2
Mekhail, T.3
Ganapathi, R.4
Chai, F.5
Savage, R.E.6
-
32
-
-
70350228630
-
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: C-Met-driven models of leiomyosarcoma
-
19825800
-
Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: c-Met-driven models of leiomyosarcoma. Mol Cancer Ther. 2009. 8:2803-2810. doi: 10.1158/1535-7163. MCT-09-0125 PMID: 19825800
-
(2009)
Mol Cancer Ther.
, vol.8
, pp. 2803-2810
-
-
Gao, C.F.1
Xie, Q.2
Zhang, Y.W.3
Su, Y.4
Zhao, P.5
Cao, B.6
-
33
-
-
79959226237
-
Activated MET is a molecular prognosticatorand potential therapeutic target for malignant peripheral nerve sheath tumors
-
21540237
-
Torres KE, Zhu Q-S, Bill K, Lopez G, Ghadimi MP, Xie X, et al. Activated MET Is a Molecular Prognosticatorand Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors. Clin Cancer Res. 2011. 17:3943-3955. doi: 10.1158/1078-0432. CCR-11-0193 PMID: 21540237
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 3943-3955
-
-
Torres, K.E.1
Zhu, Q.-S.2
Bill, K.3
Lopez, G.4
Ghadimi, M.P.5
Xie, X.6
-
34
-
-
84926636387
-
Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer
-
Koeppen H, Januario T, Filvaroff E, Towne P, James R, Roche P, et al. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. Lab Invest. 2012.
-
(2012)
Lab Invest.
-
-
Koeppen, H.1
Januario, T.2
Filvaroff, E.3
Towne, P.4
James, R.5
Roche, P.6
-
35
-
-
84868456197
-
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
-
22684217
-
Schildhaus H-U, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012. 25:1473-1480. doi: 10.1038/modpathol.2012.102 PMID: 22684217
-
(2012)
Mod Pathol.
, vol.25
, pp. 1473-1480
-
-
Schildhaus, H.-U.1
Heukamp, L.C.2
Merkelbach-Bruse, S.3
Riesner, K.4
Schmitz, K.5
Binot, E.6
-
36
-
-
84926654592
-
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
-
Schildhaus H, Schultheis A, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, et al. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2014.
-
(2014)
Clin Cancer Res.
-
-
Schildhaus, H.1
Schultheis, A.2
Rüschoff, J.3
Binot, E.4
Merkelbach-Bruse, S.5
Fassunke, J.6
-
37
-
-
64849095162
-
Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines
-
19391661
-
Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, et al. Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines. Arch Pathol Lab Med. 2009. 133:611-612. doi: 10.1043/1543-2165-133.4.611 PMID: 19391661
-
(2009)
Arch Pathol Lab Med.
, vol.133
, pp. 611-612
-
-
Vance, G.H.1
Barry, T.S.2
Bloom, K.J.3
Fitzgibbons, P.L.4
Hicks, D.G.5
Jenkins, R.B.6
-
38
-
-
84890108571
-
Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
-
24101053
-
Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013. 31:4105-4114. doi: 10.1200/JCO.2012.47.4189 PMID: 24101053
-
(2013)
J Clin Oncol.
, vol.31
, pp. 4105-4114
-
-
Spigel, D.R.1
Ervin, T.J.2
Ramlau, R.A.3
Daniel, D.B.4
Goldschmidt, J.H.5
Blumenschein, G.R.6
-
39
-
-
84855350839
-
Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: Clinicopathological, immunohistochemical and molecular analysis of 66 cases
-
21909081
-
Mentzel T, Schildhaus HU, Palmedo G, Buttner R, Kutzner H. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol. 2012. 25:75-85. doi: 10.1038/modpathol.2011.134 PMID: 21909081
-
(2012)
Mod Pathol.
, vol.25
, pp. 75-85
-
-
Mentzel, T.1
Schildhaus, H.U.2
Palmedo, G.3
Buttner, R.4
Kutzner, H.5
-
40
-
-
84926623324
-
Preclinical evaluation of anti-MET antibodies for immunohistochemical staining
-
2014
-
Koeppen H, Lowe C, Rost S. Preclinical evaluation of anti-MET antibodies for immunohistochemical staining. J Clin Oncol. 2014. 32:5s, 2014(suppl;
-
(2014)
J Clin Oncol.
, vol.32
, pp. 5s
-
-
Koeppen, H.1
Lowe, C.2
Rost, S.3
-
41
-
-
84867526394
-
Treatment Rationale Study Design forthe MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
-
23063071
-
Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, et al. Treatment Rationale Study Design forthe MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2012. 13:500-504. doi: 10.1016/j.cllc.2012.05.009 PMID: 23063071
-
(2012)
Clinical Lung Cancer.
, vol.13
, pp. 500-504
-
-
Spigel, D.R.1
Edelman, M.J.2
Mok, T.3
O'Byrne, K.4
Paz-Ares, L.5
Yu, W.6
-
42
-
-
0033901252
-
Overexpression of the Hepatocyte Growth Factor (HGF) Receptor (Met) and Presence of a Truncated and Activated Intracellular HGF Receptor Fragment in Locally Aggressive/Malignant Human Musculoskeletal Tumors
-
10702398
-
Wallenius V, Hisaoka M, Helou K, Levan G, Mandahl N, Meis-Kindblom JM, et al. Overexpression of the Hepatocyte Growth Factor (HGF) Receptor (Met) and Presence of a Truncated and Activated Intracellular HGF Receptor Fragment in Locally Aggressive/Malignant Human Musculoskeletal Tumors. Am J Pathol. 2000. 156:821-829. PMID: 10702398
-
(2000)
Am J Pathol.
, vol.156
, pp. 821-829
-
-
Wallenius, V.1
Hisaoka, M.2
Helou, K.3
Levan, G.4
Mandahl, N.5
Meis-Kindblom, J.M.6
-
43
-
-
84926675859
-
Predictive biomarker profiling of > 1, 900 sarcomas: Identification of potential novel treatment modalities
-
abstr10509 2014
-
Movva S, Wen W, Chen W, Millis SZ, Von Mehren M, Gatalica Z, et al. Predictive biomarker profiling of > 1, 900 sarcomas: Identification of potential novel treatment modalities. J Clin Oncol 32:5s, 2014(suppl:; abstr10509). 2014.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Movva, S.1
Wen, W.2
Chen, W.3
Millis, S.Z.4
Von Mehren, M.5
Gatalica, Z.6
-
44
-
-
84890254448
-
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
-
24101045
-
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013. 31:3997-4013. doi: 10.1200/JCO.2013.50.9984 PMID: 24101045
-
(2013)
J Clin Oncol.
, vol.31
, pp. 3997-4013
-
-
Wolff, A.C.1
Hammond, M.E.H.2
Hicks, D.G.3
Dowsett, M.4
McShane, L.M.5
Allison, K.H.6
-
45
-
-
73349140213
-
EGFRfluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer
-
19861557
-
Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, et al. EGFRfluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol. 2009. 62:970-977. doi: 10.1136/jcp. 2009.066548 PMID: 19861557
-
(2009)
J Clin Pathol.
, vol.62
, pp. 970-977
-
-
Varella-Garcia, M.1
Diebold, J.2
Eberhard, D.A.3
Geenen, K.4
Hirschmann, A.5
Kockx, M.6
-
46
-
-
84902811306
-
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)
-
Camidge DR, Ou S-H I, Shapiro G, Otterson GA, Cosca Villaruz L, Villalona-Calero MA, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014(suppl:;
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Camidge, D.R.1
Ou, I.S.-H.2
Shapiro, G.3
Otterson, G.A.4
Cosca Villaruz, L.5
Villalona-Calero, M.A.6
|